Article Text

Download PDFPDF
Original research
Late-onset riboflavin transporter deficiency: a treatable mimic of various motor neuropathy aetiologies
  1. Christophe Carreau1,
  2. Charline Benoit2,
  3. Guido Ahle3,
  4. Cécile Cauquil4,
  5. Agathe Roubertie5,
  6. Timothée Lenglet6,
  7. Jeremy Cosgrove7,
  8. Isabelle Meunier8,
  9. Alice Veauville-Merllié9,
  10. Cécile Acquaviva-Bourdain9,
  11. Yann Nadjar1
  1. 1 Department of Neurology, Reference Center for Lysosomal Diseases, Neuro-Metabolism Unit, AP-HP, Hôpital Universitaire Pitié Salpêtrière, Paris, France
  2. 2 Department of Neurology, AP-HP, Hôpital Universitaire Pitié Salpêtrière, Paris, France
  3. 3 Neurology, Hôpital Louis Pasteur, Colmar, Alsace, France
  4. 4 Neurology, Hôpital Bicêtre, Le Kremlin-Bicêtre, Île-de-France, France
  5. 5 Neuropediatrie, Hôpital Gui de Chauliac Pôle Neurosciences tête et cou, Montpellier, Languedoc-Roussillon Midi, France
  6. 6 Department of Neurophysiology, AP-HP, Hôpital Universitaire Pitié Salpêtrière, Paris, France
  7. 7 Neurology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  8. 8 Ophthalmology, Hôpital Gui de Chauliac, Montpellier, Languedoc-Roussillon, France
  9. 9 Laboratory of Inborn Errors of Metabolism, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France
  1. Correspondence to Dr Yann Nadjar, Neurology, Hôpital Universitaire Pitié Salpêtrière, Paris 75013, France; yann.nadjar{at}aphp.fr

Abstract

Objective Riboflavin transporter deficiencies (RTDs), involving SLC52A3 and SLC52A2 genes, have recently been related to Brown-Vialetto-Van Laere (BVVL) syndrome, a hereditary paediatric condition associating motor neuropathy (MN) and deafness. BVVL/RTD has rarely been reported in adult patients, but is probably underdiagnosed due to poor knowledge and lack of awareness of this form of disease among neurologists. In this study, we aimed to investigate the phenotype and prognosis of RTD patients with late-onset MN.

Methods We retrospectively collected clinical, biological and electrophysiological data from all French RTD patients with MN onset after 10 years of age (n=6) and extracted data from 19 other similar RTD patients from the literature.

Results Adult RTD patients with MN had heterogeneous clinical presentations, potentially mimicking amyotrophic lateral sclerosis or distal hereditary motor neuropathy (56%), multinevritis with cranial nerve involvement (16%), Guillain-Barré syndrome (8%) and mixed motor and sensory neuronopathy syndromes (20%, only in SLC52A2 patients). Deafness was often diagnosed before MN (in 44%), but in some patients, onset began only with MN (16%). The pattern of weakness varied widely, and the classic pontobulbar palsy described in BVVL was not constant. Biochemical tests were often normal. The majority of patients improved under riboflavin supplementation (86%).

Interpretation Whereas late-onset RTD may mimic different acquired or genetic causes of motor neuropathies, it is a diagnosis not to be missed since high-dose riboflavin per oral supplementation is often highly efficient.

Statistics from Altmetric.com

Footnotes

  • Contributors CC and YN contributed equally in the conception of the manuscript, the acquisition of the data and drafting of a significant portion of the manuscript and the figure. CB contributed in drafting and editing a significant portion of the manuscript and the figure. GA, CC, AR, TL, JC, AV-M and CA contributed in drafting and editing a significant portion of the manuscript. All authors approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests YN received speech honoraria from Actelion and Orphan Europe, and received travel funding from Actelion, Shire and Genzyme.

  • Patient consent for publication Obtained.

  • Ethics approval This study was conducted in compliance with the French legislation and was authorised by the national committee for the protection of privacy and personal data (CNIL, no: 2211991). Patients were informed about the use of their deidentified data in this study.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles